<DOC>
	<DOCNO>NCT02016807</DOCNO>
	<brief_summary>RATIONALE : Polymerized ( cross-linked ) sucralfate malate paste ( ProThelial ) may effective single therapy approach management chemoradiation mucositis , treat prevent occurrence oral cavity , esophagus , stomach , small large intestine . PURPOSE : This observational multi-phase trial study well polymerize ( cross-linked ) sucralfate malate paste ( ProThelial ) work prevent treat mucositis adult patient receive receive chemo/radiation therapy cause anticipated cause mucositis oral cavity , esophagus , stomach , small large intestine . The Phase IV study address prevention treatment oral cavity . The Phase I study address prevention treatment esophagus , stomach , small large intestine .</brief_summary>
	<brief_title>ZeroTolerance Mucositis : Managing Oral Alimentary Mucositis With High Potency Sucralfate - ProThelial</brief_title>
	<detailed_description>OBJECTIVES : Primary - Observe incidence mucositis patient receive ProThelial prior develop chemoradiation mucositis oral cavity , esophagus , stomach , small large intestine . - Observe change baseline symptom &amp; sign mucositis chemoradiation patient Prothelial develop mucositis oral cavity , esophagus , stomach , small large intestine . Secondary - Patient-reported quality relief ProThelial ( treatment portion ) Using Pain Visual Analogue Scale ( PVAS ) Using Difficulty Swallowing Visual Analogue Scale ( DSVAS ) - To evaluate safety tolerability ProThelial ( Phase I non-oral us ) - To observe adverse event profile ProThelial use patient-reported Questionnaire - To observe effect pain assess day 1 , 2,4,7,14,21 Pain VAS - To observe effect oral ulceration assess day 1 , 2,4,7,14,21 OMAS - To observe effect symptom esophageal mucositis assess day1 , 2,4,7,14 , 21using Difficulty Swallowing Visual Analogue Scale - To observe effect symptom gastric small intestine mucositis assess day 1,2,4,7,14,21 use Nausea Visual Analogue Scale &amp; NCI GI Toxicity Scale Nausea , Vomiting - To observe effect symptom large intestine mucositis assess day 1,2,4,7,14,21 NCI GI Toxicity Scale Colonic Diarrhea Tertiary - Functional status prior follow use ProThelial ( ECOG/Karnofsky ) patient mucositis OUTLINE : This multicenter observation study 3 treatment cohort 3 prevention cohort . Patients stratify accord gender , age , treatment , cancer treatment ( type &amp; stage ) , presence , type , &amp; severity mucositis . - Treatment ( active mucositis ) : Patients group accordance type mucositis experience - oral/esophageal , gastric/small intestine &amp; colonic . - ▪ Arm 1 Patients oroesophageal mucositis ( pain , erythema , ulceration difficult pain swallow prominent symptom/signs ) ( Phase I ) - ▪ Arm 2 Patients gastric/small intestinal mucositis ( delay nausea vomit prominent symptom/sign ) . ( Phase I ) - ▪ Arm 3 Patients chemoradiation diarrhea prominent symptom/sign . ( Phase I ) - Prevention ( mucositis ) : Patients group accordance type mucositis anticipate - oral/esophageal , gastric/small intestine colonic . - ▪ Arm 4 Patients anticipate develop oroesophageal mucositis ( pain , erythema , ulceration difficult pain swallow prominent symptom/signs ) . ( Phase IV ) - ▪ Arm 5 Patients anticipate develop gastric/small intestinal mucositis ( delay nausea vomit prominent symptom/sign ) ( Phase I ) - ▪ Arm 6 Patients anticipate develop chemoradiation diarrhea prominent symptom/sign . ( Phase I ) BACKGROUND ON INTERVENTION : PROTHELIAL™ Polymerized High Potency Sucralfate Malate Paste STANDARD POTENCY VS HIGH POTENCY SUCRALFATE IN MANAGING MUCOSITIS Standard potency non-polymerized sucralfate recommend MASCC/ISOO ( Multinational Association Supportive Care Cancer/ International Society Oral Oncology ) treatment prevention mucositis , oral alimentary . However high potency polymerize sucralfate associate rapid amelioration prevention oral alimentary mucositis patient advance head neck cancer treat simultaneously high dose chemo-radiation . High potency sucralfate standard sucralfate polymerize 'sucralfate sheet ' adhere orderly layer upon mucosa achieve maintain elevated concentration sucralfate long initial dose administration . Three hour follow administration , high potency sucralfate maintain 7 fold great surface concentration sucralfate normal line 23 fold great concentration inflame , ulcerated mucosa . In August 2013 , FDA clear use ProThelial , polymerize high potency sucralfate paste , device management oral mucositis . RAPID HEALING BY STANDARD POTENCY SUCRALFATE AT HIGH DOSES Early sucralfate investigation show undissolved ( thus high dose concentration ) sucralfate adherent human gastric mucosa cause rapid mucosal change within 10-60 minute . These change include release mucus bicarbonate well vacuolization exfoliation superficial enterocytes replace newly regenerate cell . Laboratory animal give high dos standard potency sucralfate ( 3-20 time standard 14mg/kg dose ) observe resist gastric injury , rapidly heal mucosal injury show increased secretion luminal prostaglandin , mucus bicarbonate . These mucosal change show link local expression growth factor receptor secretion epidermal growth factor . Later research identify sucralfate-mediated mucosal change growth factor dependent . Independently investigator conclude sucralfate accelerates growth-factor mediate mucosal healing , though mechanism unclear . RAPID HEALING BY HIGH POTENCY SUCRALFATE GIVEN AT LOW DOSES High potency sucralfate active ingredient ProThelial . At standard 14mg/kg dos , high potency sucralfate cause 7-23 fold hyper-concentration sucralfate mucosal line . In placebo control , double blind multi-center trial involve 60 patient , 28 day 87.7 % heal rate GERD erosion ( compare placebo 's 37.7 % ) patient use high potency sucralfate 1.5 gram twice daily . This represent 2.34 fold 334 % improvement heal placebo . Esophageal erosion treatment group expose untreated gastric acid make result observe high potency sucralfate much remarkable . Similarly , randomize 7 day four-arm trial involve 41 patient erosive GERD , rate healing patient use high potency sucralfate 80 % . The 7 day heal rate acid therapy group considerably low : omeprazole ( 20mg bid ) 30 % ranitidine ( 150mg bid ) antacid group heal 0 % . Apparently topical coat high potency sucralfate affect mucosa-centric mechanism heal appear indifferent gastric pH acid exposure . Comparing 7 day heal rate high potency sucralfate omeprazole 2.67 367 % improvement similar see high potency sucralfate compare placebo 2.34 fold 334 % improvement . EXPERIENCE USING HIGH POTENCY SUCRALFATE FOR ORAL &amp; ALIMENTARY MUCOSITIS IN STAGE 4B HEAD AND NECK CANCER In 42 yo head neck patient treat simultaneously paclitaxel , carboplatin radiation ( 201Gy ) , high potency sucralfate ( HPS - ProThelial ) prevent mucositis , allow continuance standard oral diet . The percutaneous gastric-tube surgically place anticipation Grade 3-4 mucositis never use patient . While ProThelial , patient never develop mucositis . Noncompliant discontinuation HPS patient midway chemo-radiation lead emergence oral alimentary mucositis oral erythema , nausea diarrhea . Two day follow resumption HPS , oral alimentary mucositis disappear . Throughout treatment ProThelial normal oral diet maintain analgesia require mucositis . Patient report adverse event HPS 6 week . PROTHELIAL 'S DEVICE MECHANISM OF ACTION - EXPEDITED HEALING High potency sucralfate polymerize sucralfate malate paste device mechanism action . It assume efficient layer polymerized sucralfate paste produce adherent restrictive microenvironment across mucosal lining advantage activation growth factor receptor growth factor . Restrictive micro-environs generate cross-linked layer polymerize sucralfate `` crowd '' free-moving growth factor , limit random movement `` pocket '' overlie growth factor receptor . Spatially limit movement growth factor vicinity receptor heighten chance receptor site activation . This device action lead expedite healing . PROTHELIAL 'S DEVICE MECHANISM OF ACTION - REVERSING MUCOSA-BASED PAIN , NAUSEA , VOMITING &amp; DIARRHEA The surface `` pocket '' restrictive micro-environs create Prothelial 's unique layering probably affect flux ion across mucosal receptor responsible pain , nausea , vomit neuro-secretory diarrhea . These specialized mucosal receptor trigger chemo-radiation maintain state activation mean gated-ion flux across surface membrane face lumen gut . It probable restrictive micro-environs crowd growth factor vicinity receptor also affect surround space available membrane ion-flux exchange . Spatial limitation immediate surface environment surround ion-gated receptor along GI tract impact receptor 's ability perpetuate ion flux require keep receptor `` turn '' stimulate . Physically restrictive micro-environs surround membrane stimulate receptor exhaust ion immediately available exchange . This limit ability receptor stay `` '' . The result quiescence membrane reduction receptor-associated pain , nausea ( thereby vomit ) neurosecretory diarrhea , trigger chemoradiation therapy .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Sucralfate</mesh_term>
	<criteria>18 year old Informed consent Patients receive cancer therapy agent likely cause mucositis Patients develop mucositis chemo/and radiation Patients receive cause nausea , vomit Patients receive cause diarrhea Patients Head &amp; Neck cancer receive chemo/radiation GTube Patients undergo Hematopoietic Stem Cell Transplantation Absence consent Unable unwilling complete self assessment questionnaire . Use mouthwash study Simultaneous treatment agent prevention/treatment mucositis Patients baseline creatinine level great equal 3 patient renal insufficiency require dialysis Have know allergy intolerance ProThelial ingredient ( sucralfate )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Mucositis</keyword>
	<keyword>Sucralfate</keyword>
	<keyword>Prothelial</keyword>
	<keyword>High potency sucralfate</keyword>
	<keyword>Ulcerations</keyword>
	<keyword>Chemotherapy induce diarrhea</keyword>
	<keyword>Radiation induce mucositis</keyword>
	<keyword>Chemotherapy colitis</keyword>
	<keyword>Radiation colitis</keyword>
	<keyword>Mucosal erosion</keyword>
</DOC>